OncoOne

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics! Our platform for pre-targeted radioimmunotherapy is featured as the First Disclosure and cover story in this month’s AACR journal Molecular Cancer Therapeutics (MCT). Our innovative two-step regimen is set to revolutionize the delivery of radioactive payloads in cancer treatment. #OncoOne #PreTargit #CancerResearch #Radioimmunotherapy #AACR #radiopharmaceuticals #theranostic   Discover more about our findings here: https://lnkd.in/eNZAM6jE

OncoOne’s PreTarg-it® Platform shines on the cover of Molecular Cancer Therapeutics! Our platform for pre-targeted radioimmunotherapy is featured as the First Disclosure and cover story in this month’s AACR journal Molecular Cancer Therapeutics (MCT). Our innovative two-step regimen is set to revolutionize the delivery of radioactive payloads in cancer treatment. #OncoOne #PreTargit #CancerResearch #Radioimmunotherapy #AACR #radiopharmaceuticals #theranostic   Discover more about our findings here: https://lnkd.in/eNZAM6jE

Our #Autoimmune and #InflammatoryDiseases track is coming back even stronger this year! After the success of last year, we have decided to expand this track and invite more speakers to deliver exclusive presentations. As one of the featured session on the track, Michael Thiele, Chief Scientific Officer of OncoOne will be presenting 'ON104: Pioneering Treatment for oxMIF-Driven Autoimmune Diseases' He will be diving into their leading program, ON104, a monoclonal antibody designed to target the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases. Register now to join the session 👉https://lnkd.in/eVfs_-cH #festivalofbiologics

An exciting time at BIO Asia–Taiwan! Our VP CMC, Friedmund Bachmann, delivered an insightful talk on "Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development." The session, held on July 25, highlighted our CMC development strategy for ON203, our lead candidate for treating solid tumors. Thanks to everyone who joined and engaged in the lively discussions about our innovative anti-oxMIF antibody pipeline and our PreTarg-it® technology for targeted radioimmunotherapy of solid tumors. It was a great opportunity to share our vision for advancing cancer and chronic inflammatory disease treatments. Stay tuned for more updates from OncoOne as we continue to push the boundaries of biologics development! #BioAsiaTaiwan #BiologicsDevelopment #OncoOne #oxMIF #PreTargit #CancerResearch #Innovation #Partnerships

Bio Asia-Taiwan is about to start! Don't miss the chance to schedule a one-on-one meeting with OncoOne’s VP of CMC, Friedmund Bachmann. Attend his talk, “Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development,” on July 25, from 12.30 to 12:50 in session 8. He will discuss our CMC development strategy for our lead candidate ON203 for the treatment of solid tumors. This event is also a great opportunity to explore potential partnerships and learn about our innovative anti-oxMIF antibody pipeline for cancer and chronic inflammatory diseases, as well as our PreTarg-it® technology for targeted radioimmunotherapy of solid tumors. Set up your meeting through the BIO One-on-One Partnering platform: https://lnkd.in/d9yK8CxK We look forward to seeing you in Taipei! #BioAsia2024 #oxMIF #cancer #inflammation #therapy #partnering

Brown University and OncoOne publish key aspects of oxMIF biology in Redox Biology. Binding of (ox)MIF to its receptor CD74 is influenced by redox conditions. This proves once again that structural changes influenced by environmental conditions are an important regulatory mechanism and emphasises the great potential of OncoOne's portfolio targeting oxMIF. Please follow the link to access the article: https://lnkd.in/dVqm2iCY A big thanks to George Lisi and his amazing team at Brown University for their invaluable scientific contributions! #oxMIF #ON104 #inflammation #redoxbiology

We are excited to share that our CSO, Michael Thiele, was invited to contribute a textbook chapter on (ox)MIF in innate tumor immunity for the Elsevier Reference Collection in Life Sciences! Here’s the link to the chapter: https://lnkd.in/dRYq-p4n. It's fantastic to see the scientific community increasingly acknowledge our CSO's expertise in MIF and its pathological isoform, oxMIF, along with the outstanding work of our team. We take pride in pioneering breakthroughs targeting oxMIF and developing innovative treatment options.

🌟 Memorable Moments at EULAR2024! 🌟 We had the incredible opportunity to dine and exchange ideas with the MIF Pope Rick Bucala from Yale and the esteemed pharmacologist Michael Freissmuth from the Medical University of Vienna. Their insights and experiences made for an inspiring evening. Feeling grateful for such enriching conversations and for their support in the clinical development of ON104.  #MIF #Rheumatology #EULAR2024 #ON104

Join Christine Landlinger-Schubert, PhD, our VP of Preclinical and Translational R&D, at #EULAR2024 in Vienna today. She will lead a poster presentation on our lead candidate, #ON104, titled “Targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF) with antibody ON104: a promising therapeutic approach for Rheumatoid Arthritis.” Don't miss it from 12:00 to 13:30 CEST in Poster Tour 3. Check out the full agenda: https://lnkd.in/dE4_Q-uS

We are excited to share our new publication in AACR Journals Molecular Cancer Therapeutics! Our latest study presents promising results from pretargeted radioimmunotherapy using the novel PreTarg-it® antibody ON105. Discover more about our findings here: https://lnkd.in/gyUi26Yv Congratulations to first authors Alejandro P. Puchol and Alexander Schinagl for their remarkable contributions. We also want to express our gratitude to MCT for publishing our work and for the smooth editorial process, especially to Danielle Large for her invaluable support.